Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1984 Jul;82(3):745–755. doi: 10.1111/j.1476-5381.1984.tb10814.x

Recovery of beta-adrenoceptors and cyclic AMP response after long term treatment of intact heart cells with beta-blockers.

C Becker, H Porzig
PMCID: PMC1987018  PMID: 6146370

Abstract

We have studied the recovery of receptor binding and of isoprenaline-stimulated cyclic AMP responses after chronic (2-5 days) exposure of tissue-cultured living rat heart cells to several beta-adrenoceptor antagonists. Most experiments were performed with [3H]- (+/-)-carazolol and [3H]-(+/-)-CGP 12177, as prototypes of high affinity lipophilic and hydrophilic ligands respectively. Chronic antagonist treatment did not alter the total number of receptors nor did it cause intracellular accumulation of the ligands. At the end of the treatment, radiolabelled antagonists were displaced either by 'infinite' dilution of the incubation medium or by competitive displacement with the non-labelled ligand (-)-timolol. In dilution assays dissociation of carazolol from specific sites was biphasic with t 1/2 values of 41 +/- 14 and 219 +/- 15 min. Dissociation of CGP 12177 was monophasic with t 1/2 of 102 +/- 2 min. Timolol enhanced the dissociation rates of both radioligands and suppressed the slow phase of carazolol dissociation. Isoprenaline-stimulated cyclic AMP formation did not recover in parallel with the release of the two antagonists from receptor binding sites. To reach about 80% of control values for receptor availability or cyclic AMP response required 3 h and 24 h washout periods, respectively, after carazolol (0.2 nM) treatment, or 1.5 and 12 h washout periods after CGP 12177 (4 nM) treatment. Such a 'decoupling' effect was not observed during recovery from chronic exposure to the antagonists, timolol and propranolol. We conclude that some antagonists cause a novel form of desensitization that is not linked to their partial agonistic potency. Moreover, carazolol-type drugs seem to induce an additional isomeric form of the beta-receptor that is not recognized by other antagonists. These observations could explain the well known discrepancy between long duration of action and rapid removal from the circulation of several antagonists in current therapeutic use.

Full text

PDF
745

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bürgisser E., Lefkowitz R. J., DeLean A. Alternative explanation for the apparent "two-step" binding kinetics of high-affinity racemic antagonist radioligands. Mol Pharmacol. 1981 May;19(3):509–512. [PubMed] [Google Scholar]
  2. Franklin T. J., Twose P. A. Desensitization of beta receptor mediated cyclic AMP response of cultured fibroblasts by partial agonists. J Cyclic Nucleotide Res. 1979;5(1):19–30. [PubMed] [Google Scholar]
  3. Galper J. B., Klein W., Catterall W. A. Muscarinic acetylcholine receptors in developing chick heart. J Biol Chem. 1977 Dec 10;252(23):8692–8699. [PubMed] [Google Scholar]
  4. Innis R. B., Corrēa F. M., Synder S. H. Carazolol, an extremely potent beta-adrenergic blocker: binding to beta-receptors in brain membranes. Life Sci. 1979 Jun 11;24(24):2255–2264. doi: 10.1016/0024-3205(79)90102-4. [DOI] [PubMed] [Google Scholar]
  5. Insel P. A., Mahan L. C., Motulsky H. J., Stoolman L. M., Koachman A. M. Time-dependent decreases in binding affinity of agonists for beta-adrenergic receptors of intact S49 lymphoma cells. A mechanism of desensitization. J Biol Chem. 1983 Nov 25;258(22):13597–13605. [PubMed] [Google Scholar]
  6. Klein W. L. Multiple binding states of muscarinic acetylcholine receptors in membranes from neuroblastoma x glioma hybrid cells. Biochem Biophys Res Commun. 1980 Apr 29;93(4):1058–1066. doi: 10.1016/0006-291x(80)90596-3. [DOI] [PubMed] [Google Scholar]
  7. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  8. Manalan A. S., Besch H. R., Jr, Watanabe A. M. Characterization of [3H](+/-)carazolol binding to beta-adrenergic receptors. Application to study of beta-adrenergic receptor subtypes in canine ventricular myocardium and lung. Circ Res. 1981 Aug;49(2):326–336. doi: 10.1161/01.res.49.2.326. [DOI] [PubMed] [Google Scholar]
  9. Morris T. H., Birnbaumer L., Kaumann A. J. High affinity of carozolol for beta-adrenoceptors coupled to the adenylyl cyclase in ventricular myocardium of kitten and Xenopus laevis. Naunyn Schmiedebergs Arch Pharmacol. 1978 Jul;303(3):295–297. doi: 10.1007/BF00498057. [DOI] [PubMed] [Google Scholar]
  10. Pittman R. N., Molinoff P. B. Interactions of agonists and antagonists with beta-adrenergic receptors on intact L6 muscle cells. J Cyclic Nucleotide Res. 1980;6(6):421–435. [PubMed] [Google Scholar]
  11. Pittman R. N., Molinoff P. B. Interactions of full and partial agonists with beta-adrenergic receptors on intact L6 muscle cells. Mol Pharmacol. 1983 Nov;24(3):398–408. [PubMed] [Google Scholar]
  12. Porzig H., Becker C., Reuter H. Competitive and non-competitive interactions between specific ligands and beta-adrenoceptors in living cardiac cells. Naunyn Schmiedebergs Arch Pharmacol. 1982 Nov;321(2):89–99. doi: 10.1007/BF00518474. [DOI] [PubMed] [Google Scholar]
  13. Prinz H., Maelicke A. Interaction of cholinergic ligands with the purified acetylcholine receptor protein. II. Kinetic studies. J Biol Chem. 1983 Sep 10;258(17):10273–10282. [PubMed] [Google Scholar]
  14. Prinz H. On the interpretation of equilibrium binding studies. J Recept Res. 1983;3(1-2):239–248. doi: 10.3109/10799898309041938. [DOI] [PubMed] [Google Scholar]
  15. Ross E. M., Maguire M. E., Sturgill T. W., Biltonen R. L., Gilman A. G. Relationship between the beta-adrenergic receptor and adenylate cyclase. J Biol Chem. 1977 Aug 25;252(16):5761–5775. [PubMed] [Google Scholar]
  16. Staehelin M., Simons P., Jaeggi K., Wigger N. CGP-12177. A hydrophilic beta-adrenergic receptor radioligand reveals high affinity binding of agonists to intact cells. J Biol Chem. 1983 Mar 25;258(6):3496–3502. [PubMed] [Google Scholar]
  17. Staehelin M., Simons P. Rapid and reversible disappearance of beta-adrenergic cell surface receptors. EMBO J. 1982;1(2):187–190. doi: 10.1002/j.1460-2075.1982.tb01145.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Su Y. F., Harden T. K., Perkins J. P. Catecholamine-specific desensitization of adenylate cyclase. Evidence for a multistep process. J Biol Chem. 1980 Aug 10;255(15):7410–7419. [PubMed] [Google Scholar]
  19. Terasaki W. L., Brooker G. [125I]Iodohydroxybenzylpindolol binding sites on intact rat glioma cells. Evidence for beta-adrenergic receptors of high coupling efficiency. J Biol Chem. 1978 Aug 10;253(15):5418–5425. [PubMed] [Google Scholar]
  20. Toews M. L., Harden T. K., Perkins J. P. High-affinity binding of agonists to beta-adrenergic receptors on intact cells. Proc Natl Acad Sci U S A. 1983 Jun;80(12):3553–3557. doi: 10.1073/pnas.80.12.3553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Tovey K. C., Oldham K. G., Whelan J. A. A simple direct assay for cyclic AMP in plasma and other biological samples using an improved competitive protein binding technique. Clin Chim Acta. 1974 Nov 8;56(3):221–234. doi: 10.1016/0009-8981(74)90133-8. [DOI] [PubMed] [Google Scholar]
  22. Wolfe B. B., Harden T. K. Guanine nucleotides modulate the affinity of antagonists at beta-adrenergic receptors. J Cyclic Nucleotide Res. 1981;7(5):303–312. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES